Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms, Hereditary Nonpolyposis 2Colorectal Neoplasms 2Recurrence 1Neoplasms 1Colonic Neoplasms 1Adenoma 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × Mesalamine × Clear all
NCT03070574 2019-04-18

MesaCAPP

Medical University of Vienna

Phase 2 Terminated
8 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02077777 2016-12-02

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

SOFAR S.p.A.

Phase 2 Completed
21 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡